⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 9, 2024Neurology

Long-term Maintenance of ≥50% Migraine Response with Eptinezumab Treatment in Patients with 2–4 Prior Preventive Migraine Treatment Failures (S22.008)

Jessica Ailani Seema Soni-Brahmbhatt Susanne F. Awad Xin Ying Lee Bjørn Sperling Richard B. Lipton

View at Publisher

Ask AI

Bookmark

Share

Abstract

To evaluate the 18-month maintenance of ≥50% migraine response in patients who experienced ≥50% migraine response with early doses of eptinezumab.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ailani et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdadb6db643587677c80 https://doi.org/10.1212/wnl.0000000000204563

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III StudyObservational Study · 2026 · 1 citations
2P.005 Eptinezumab demonstrated efficacy regardless of prior preventive migraine treatment failure: post hoc DELIVER analyses2024
3Real-world Effectiveness of Eptinezumab in Chronic Migraine: A 4-year Retrospective Longitudinal Cohort Study (P10-15.003)Cohort Study · 2026
4Early and Sustained Shift in Headache Day Frequency Following Eptinezumab Treatment in Adults With Migraine for Whom 2–4 Previous Preventive Treatments Have Failed: A Post Hoc Analysis of the Randomized <scp>DELIVER</scp> TrialRCT · 2025 · 2 citations
5A 24-week prospective, multicenter, real-world study on eptinezumab’s effectiveness and safety in migraine prevention (EMBRACE II)Cohort Study · 2025 · 14 citations

Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab2022
Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review2024
Testing the Efficacy of Eptinezumab 100 mg in the Early Prevention of Chronic Migraine over Weeks 1 to 4: Prospective Real-World Data from the GRASP Study Group2025
Cenobamate in Focal-Onset Refractory and Super-Refractory Status EpilepticusNeurology · 2026
Exclusion of Arteriovenous Shunts in Intracerebral Hemorrhage Using MRI Arterial Spin LabelingNeurology · 2026

More from Neurology

More from Albert Einstein College of Medicine

More from Georgetown University

More from Lundbeck (Denmark)

More from Lundbeck (Germany)